Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumoursIgnacio Melero, Thomas F. Gajewski, Juan Martín-Liberal et al.|Nature|2024Cited by 107
Clinical outcomes of abiraterone acetate + prednisone (AA) + bone resorption inhibitors (BRI) versus AA alone as first-line therapy for castration-resistant prostate cancer (CRPC) with bone metastases (BM) in an international multicenter database.Edoardo Francini, Daniel Yick Chin Heng, Francesca Montagnani et al.|Journal of Clinical Oncology|2020Cited by 1